Objective. Evaluation of the effectiveness of drug prevention of bone cement implantation syndrome in hip joint arthroplasty. Material and methods. A retrospective analysis of 400 medical records of patients who underwent hip arthroplasty was performed. In the main group (n = 200), the prevention of bone cement implantation syndrome was carried out using popular drugs (mafusol, reamberin, antihistamines, glucocorticoids). In the control group (n = 200), these drugs were not used. Blood pressure, heart rate, blood saturation were evaluated intraoperatively. In the postoperative period, fixed complications associated with anesthesia and surgery. Results. The volume of intraoperative blood loss, mean arterial pressure, heart rate and blood saturation in the main and control groups did not have significant differences. At the stage of cementing the bone canal, hypotension developed in 95% and 95.5% of cases, respectively. 2 patients (1.0%) of the first group developed a stress-related ulcer bleeding on the 3rd day of the postoperative period, one patient (0.5%) had an Ischemic stroke on the 5th day after the operation, in three patients (1.5%) atrial fibrillation paroxysm during the week after surgery. Three (1.5%) patients developed a skin allergic reaction to reamberin. In the second group, there were two cases (1.0%) of Ischemic stroke within a week after surgery and one cases (0.5%) of acute myocardial infarction on the 5th day after surgical treatment. Conclusion. There is no need for intraoperative drug prevention of bone cement implantation syndrome. Additional pharmacological load increases the risk of side effects and complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.